The quarterly 13F filing season lets us peek into the minds of top investors. Health care stocks were in during the quarter, while techs were out. Read More

Pipeline companies are accustomed to navigating the thicket of regulatory requirements, but now they’re also learning how to win the war of public relations. Read More

This blue chip pharmaceutical firm has taken it on the chin lately, but several new drugs in the pipeline should hold it in good stead. Read More

Investment in wireless and wireline network technology continues to rise all over the world--except in Europe. This trend might be about to change. Read More

Booming US crude supply should dramatically reduce the power of the oil exporters’ cartel, despite the market’s current skepticism. Read More

Hedge fund manager Dan Loeb’s billion-dollar new stake could pay off big even if the company spurns him. Read More

The retailer is betting big on its first foray outside the U.S. Here’s a look at its chances—and some of the domestic firms it’s facing off against. Read More

The best bets are the fastest-growing and most profitable producers. Their gains will pain suppliers of chemicals and biofuels Read More

Investor concerns about reporting transparency in China are overblown. Here's some perspective. Read More

The stock market continues to rise as the real economy remains stuck in neutral thanks to monetary stimulus. When the monetary music stops, large caps will drop based on "risk-off" macro beta but small caps will perform based on fundamentals. Read More